Tayfun Et
Karaman, 70200, Turkey (Türkiye)
NCT Number: NCT05003544
90 patients ASA I-III, undergoing Total hip arthroplasty (THA) under spinal anesthesia, will be randomly assigned into one of three groups, namely group A (n=30), where an PENG block, group B (N:30) where an inra-articuler, and group C (n=30) where Quadratus lumborum block will be performed preoperatively. All patients will receive a standardized postoperative analgesia regimen. NRS scores will be evaluated in static and dynamic conditions during the first 48 hours postoperatively.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Not applicable
Karaman, 70200, Turkey (Türkiye)
Total hip arthroplasty (THA) is the second most common joint replacement surgery, partly due to the aging population. The primary aim of this study is to compare the analgesic efficacy of Pericapsular nerve group (PENG) block with intra-articular and Quadrotus lumborum block (QLB). Regional anesthesia (RA), such as the recently described pericapsular nerve group (PENG) block, may provide additional analgesic benefit in this situation. Pericapsular nerve group (PENG) block is a new regional anesthesia technique to provide analgesia after hip fractures and hip arthroplasty. The aim of this single-center, double-blind, randomized controlled trial is to confirm the efficacy of PENG block for postoperative recovery after primary THA.
Routine multimodal analgesia will be used for postoperative analgesia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PENG BLOCK
Intra-articular
Quadratus lumborum block
Time frame: 48 Hours
Range 0-10, 0=no pain, 10=the worse pain ever
Time frame: 3-6-8-12-24 and 48 hours
Analgesic consumption
Time frame: 3-6-8-12-24 and 48 hours
Pain intensity at rest and during active movement using a numeric rating score (NRS) 0 = no pain and 10 = worst imaginable painranged from 0 to 10
Time frame: 3-6-12-24 hours after the block
Quadriceps motor function will be tested with the patient supine and with the hip and knee flexed at 45º and 90º, respectively. The subject will be asked to extend the knee first against gravity and then against resistance. Quadriceps strength will be graded according to a 3-point scale: normal strength = 0 point (extension against resistance); paresis = 1 point (extension against gravity but not against resistance); and paralysis = 2 points (no extension).
Time frame: 3-6-12-24 hours after the block
Hip adduction will be evaluated by comparing it to baseline strength (i.e., prior to spinal anesthesia). A blood pressure cuff, inflated at 40 mmHg, will be inserted between the knees of the patient: the latter will then be instructed to squeeze the cuff as hard as possible and to sustain the effort. We will define hip adduction scores of 0, 1 and 2 points as decreases in strength of 0-20%, 21-70% and 71-90% compared to baseline measurement, respectively
Time frame: 3-6-12-24 hours after the block
Presence of postoperative nausea, vomiting, pruritus, urinary retention, respiratory depressio
Time frame: 48 hours
Patients asked whether they would choose the same anaesthetic management in a future operation: Yes/No
Time frame: measurements are obtained at 24 hours, 48 hours, and one week
QoR-40, a 40-item questionnaire that provides a global score and sub-scores across five dimensions: patient support, comfort, emotions, physical independence, and pain. Each item is rated on a scale of 1-5, providing a minimum score of 40 and maximum of 200.
Time frame: 24 hour
Mobilization time
Karaman Training and Research Hospital
Other
Comparıson Of PENG Block wıth Intra-articular And Quadratus Lumborum Block İn Primary Total Hip Arthroplasty: : Randomized Controlled Double Blinded Trial Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06096155
Hip Arthropathy
Challans, Vendée, France
View Trial DetailsNCT05446623
Hip Arthropathy, Hip Disease
Montauban, Tarn et Garonne, France
View Trial DetailsNCT07023120
Arthritis, Hip Arthritis
Poznan, Poland
View Trial DetailsNCT07023107
Arthritis, Hip Arthropathy
Poznan, Poland
View Trial Details